PharmaCyte Biotech (PMCB) Return on Equity (2016 - 2026)
PharmaCyte Biotech (PMCB) has disclosed Return on Equity for 15 consecutive years, with 0.05% as the latest value for Q4 2025.
- On a quarterly basis, Return on Equity fell 14.0% to 0.05% in Q4 2025 year-over-year; TTM through Oct 2025 was 0.05%, a 14.0% decrease, with the full-year FY2025 number at 0.07%, down 14.0% from a year prior.
- Return on Equity was 0.05% for Q4 2025 at PharmaCyte Biotech, up from 0.06% in the prior quarter.
- In the past five years, Return on Equity ranged from a high of 0.12% in Q2 2024 to a low of 0.61% in Q3 2021.
- A 5-year average of 0.1% and a median of 0.06% in 2023 define the central range for Return on Equity.
- Peak YoY movement for Return on Equity: soared 55bps in 2022, then fell -18bps in 2025.
- PharmaCyte Biotech's Return on Equity stood at 0.08% in 2021, then increased by 13bps to 0.07% in 2022, then dropped by -10bps to 0.07% in 2023, then soared by 211bps to 0.08% in 2024, then tumbled by -166bps to 0.05% in 2025.
- Per Business Quant, the three most recent readings for PMCB's Return on Equity are 0.05% (Q4 2025), 0.06% (Q3 2025), and 0.06% (Q2 2025).